Aplaviroc (INN, codenamed AK602 and GSK-873140) is a CCR5 entry inhibitor that belongs to a class of 2,5-diketopiperazines developed for the treatment of HIV infection. It was developed by GlaxoSmithKline.
{{Infobox drug | verifiedrevid = 451871816 | IUPAC_name = 4-(4-{[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo- 1,4,9-triazaspiro[5.5]undecan-9-yl]methyl}phenoxy)benzoic acid | image = Aplaviroc structure.svg | image_class = skin-invert-image | width = 300
| pregnancy_category = | legal_status = Development terminated | routes_of_administration = Oral
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).